Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 50

1.

Ivacaftor in cystic fibrosis adults: Czech experience with six years of follow-up.

Fila L, Valentova Bartakova L, Grandcourtova A, Marel M, Drnek R, Bilkova A, Macek M, Drevinek P.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016 May 25. doi: 10.5507/bp.2016.029. [Epub ahead of print]

PMID:
27226150
2.

Breath concentration of acetic acid vapour is elevated in patients with cystic fibrosis.

Smith D, Sovová K, Dryahina K, Doušová T, Dřevínek P, Španěl P.

J Breath Res. 2016 May 17;10(2):021002. doi: 10.1088/1752-7155/10/2/021002.

PMID:
27184114
3.

Cost-of-illness analysis and regression modeling in cystic fibrosis: a retrospective prevalence-based study.

Mlčoch T, Klimeš J, Fila L, Vávrová V, Skalická V, Turnovec M, Krulišová V, Jirčíková J, Zemková D, Dědečková KV, Bílková A, Frühaufová V, Homola L, Friedmannová Z, Drnek R, Dřevínek P, Doležal T, Macek M Jr.

Eur J Health Econ. 2016 Jan 7. [Epub ahead of print]

PMID:
26743971
4.

How and why to monitor Pseudomonas aeruginosa infections in the long term at a cystic fibrosis centre.

Kalferstova L, Vilimovska Dedeckova K, Antuskova M, Melter O, Drevinek P.

J Hosp Infect. 2016 Jan;92(1):54-60. doi: 10.1016/j.jhin.2015.09.010. Epub 2015 Oct 8.

PMID:
26597636
5.

Report of the European Respiratory Society/European Cystic Fibrosis Society task force on the care of adults with cystic fibrosis.

Elborn JS, Bell SC, Madge SL, Burgel PR, Castellani C, Conway S, De Rijcke K, Dembski B, Drevinek P, Heijerman HG, Innes JA, Lindblad A, Marshall B, Olesen HV, Reimann AL, Solé A, Viviani L, Wagner TO, Welte T, Blasi F.

Eur Respir J. 2016 Feb;47(2):420-8. doi: 10.1183/13993003.00592-2015. Epub 2015 Oct 9.

PMID:
26453627
6.

Identification of bacteria from aerobic and anaerobic blood cultures after short cultivation by matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry.

Nunvar J, Drevinek P.

J Med Microbiol. 2015 Oct;64(10):1253-5. doi: 10.1099/jmm.0.000140. Epub 2015 Jul 17. No abstract available.

PMID:
26297327
7.

Phenotypic characterization of an international Pseudomonas aeruginosa reference panel: strains of cystic fibrosis (CF) origin show less in vivo virulence than non-CF strains.

Cullen L, Weiser R, Olszak T, Maldonado RF, Moreira AS, Slachmuylders L, Brackman G, Paunova-Krasteva TS, Zarnowiec P, Czerwonka G, Reilly J, Drevinek P, Kaca W, Melter O, De Soyza A, Perry A, Winstanley C, Stoitsova SR, Lavigne R, Mahenthiralingam E, Sá-Correia I, Coenye T, Drulis-Kawa Z, Augustyniak D, Valvano MA, McClean S.

Microbiology. 2015 Oct;161(10):1961-77. doi: 10.1099/mic.0.000155. Epub 2015 Aug 6.

PMID:
26253522
8.

Draft Genome Sequences of Burkholderia contaminans, a Burkholderia cepacia Complex Species That Is Increasingly Recovered from Cystic Fibrosis Patients.

Bloodworth RA, Selin C, López De Volder MA, Drevinek P, Galanternik L, Degrossi J, Cardona ST.

Genome Announc. 2015 Aug 6;3(4). pii: e00766-15. doi: 10.1128/genomeA.00766-15.

9.

Increased Prevalence and Resistance of Important Pathogens Recovered from Respiratory Specimens of Cystic Fibrosis Patients During a Decade.

Raidt L, Idelevich EA, Dübbers A, Küster P, Drevinek P, Peters G, Kahl BC.

Pediatr Infect Dis J. 2015 Jul;34(7):700-5. doi: 10.1097/INF.0000000000000714.

PMID:
25851069
10.

In vitro and in vivo antibacterial activity of environmental bacteriophages against Pseudomonas aeruginosa strains from cystic fibrosis patients.

Olszak T, Zarnowiec P, Kaca W, Danis-Wlodarczyk K, Augustyniak D, Drevinek P, de Soyza A, McClean S, Drulis-Kawa Z.

Appl Microbiol Biotechnol. 2015 Jul;99(14):6021-33. doi: 10.1007/s00253-015-6492-6. Epub 2015 Mar 12.

11.

Gene expression profiling of Burkholderia cenocepacia at the time of cepacia syndrome: loss of motility as a marker of poor prognosis?

Kalferstova L, Kolar M, Fila L, Vavrova J, Drevinek P.

J Clin Microbiol. 2015 May;53(5):1515-22. doi: 10.1128/JCM.03605-14. Epub 2015 Feb 18.

12.

Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST).

McKone EF, Borowitz D, Drevinek P, Griese M, Konstan MW, Wainwright C, Ratjen F, Sermet-Gaudelus I, Plant B, Munck A, Jiang Y, Gilmartin G, Davies JC; VX08-770-105 (PERSIST) Study Group.

Lancet Respir Med. 2014 Nov;2(11):902-10. doi: 10.1016/S2213-2600(14)70218-8. Epub 2014 Oct 9.

PMID:
25311995
13.

Possible Tyromyces fissilis (Basidiomycota, Polyporales) co-infection in a lung transplant recipient.

Chrenkova V, Kolarik M, Hubacek P, Kolarik J, Simonek J, Lischke R, Drevinek P.

Folia Microbiol (Praha). 2015 Jan;60(1):33-5. doi: 10.1007/s12223-014-0336-0. Epub 2014 Jul 27.

PMID:
25064474
14.

European Cystic Fibrosis Society Standards of Care: Framework for the Cystic Fibrosis Centre.

Conway S, Balfour-Lynn IM, De Rijcke K, Drevinek P, Foweraker J, Havermans T, Heijerman H, Lannefors L, Lindblad A, Macek M, Madge S, Moran M, Morrison L, Morton A, Noordhoek J, Sands D, Vertommen A, Peckham D.

J Cyst Fibros. 2014 May;13 Suppl 1:S3-22. doi: 10.1016/j.jcf.2014.03.009. Review.

15.

[Bacteria of the Burkholderia cepacia complex: epidemiology and diagnosis of infection in patients with cystic fibrosis].

Dřevínek P.

Epidemiol Mikrobiol Imunol. 2014 Feb;63(1):18-26. Review. Czech.

PMID:
24730990
16.

Developing an international Pseudomonas aeruginosa reference panel.

De Soyza A, Hall AJ, Mahenthiralingam E, Drevinek P, Kaca W, Drulis-Kawa Z, Stoitsova SR, Toth V, Coenye T, Zlosnik JE, Burns JL, Sá-Correia I, De Vos D, Pirnay JP, Kidd TJ, Reid D, Manos J, Klockgether J, Wiehlmann L, Tümmler B, McClean S, Winstanley C; EU FP7 funded COST Action BM1003 “Cell surface virulence determinants of cystic fibrosis pathogens”.

Microbiologyopen. 2013 Dec;2(6):1010-23. doi: 10.1002/mbo3.141. Epub 2013 Nov 11.

17.

Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS patient registry.

Kerem E, Viviani L, Zolin A, MacNeill S, Hatziagorou E, Ellemunter H, Drevinek P, Gulmans V, Krivec U, Olesen H; ECFS Patient Registry Steering Group.

Eur Respir J. 2014 Jan;43(1):125-33. doi: 10.1183/09031936.00166412. Epub 2013 Apr 18.

18.

Novel diagnostic PCR assay for Burkholderia cenocepacia epidemic strain ST32 and its utility in monitoring infection in cystic fibrosis patients.

Dedeckova K, Kalferstova L, Strnad H, Vavrova J, Drevinek P.

J Cyst Fibros. 2013 Sep;12(5):475-81. doi: 10.1016/j.jcf.2012.12.007. Epub 2013 Jan 11.

19.

Reference percentiles for FEV(1) and BMI in European children and adults with cystic fibrosis.

Boëlle PY, Viviani L, Busson PF, Olesen HV, Ravilly S, Stern M, Assael BM, Barreto C, Drevinek P, Thomas M, Krivec U, Mei-Zahav M, Vibert JF, Clement A, Mehta A, Corvol H; French CF Modifier Gene Study Investigators; European CF Registry Working Group.

Orphanet J Rare Dis. 2012 Sep 7;7:64. doi: 10.1186/1750-1172-7-64.

20.

PCR detection of Burkholderia cepacia complex as one of key factors to handle a long-term outbreak.

Dedeckova K, Fila L, Skalicka V, Bartosova J, Kucerova T, Vavrova V, Zemkova D, Kalferstova L, Melter O, Cinek O, Drevinek P.

J Cyst Fibros. 2012 Sep;11(5):440-5. doi: 10.1016/j.jcf.2012.04.005. Epub 2012 May 22.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk